Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Consensus Target Price from Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has earned an average rating of "Moderate Buy" from the eight analysts that are presently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $56.33.

AGIO has been the topic of a number of recent research reports. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, November 9th. Scotiabank boosted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, December 9th. Royal Bank of Canada raised their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research report on Tuesday, December 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Finally, Raymond James reiterated an "outperform" rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now owns 18,906 shares of the company's stock, valued at $608,395.08. The trade was a 12.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 4.93% of the company's stock.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in AGIO. Mirae Asset Global Investments Co. Ltd. boosted its stake in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 363 shares during the period. KBC Group NV boosted its position in shares of Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 611 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock valued at $539,000 after acquiring an additional 688 shares in the last quarter. Inspire Investing LLC increased its holdings in Agios Pharmaceuticals by 13.7% during the 3rd quarter. Inspire Investing LLC now owns 9,228 shares of the biopharmaceutical company's stock worth $410,000 after acquiring an additional 1,113 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Agios Pharmaceuticals by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,092 shares of the biopharmaceutical company's stock worth $397,000 after purchasing an additional 1,150 shares during the period.

Agios Pharmaceuticals Stock Up 2.5 %

AGIO stock traded up $0.85 during midday trading on Thursday, reaching $34.58. 151,611 shares of the company's stock traded hands, compared to its average volume of 791,923. The company has a 50-day simple moving average of $41.15 and a two-hundred day simple moving average of $44.56. Agios Pharmaceuticals has a 1-year low of $22.23 and a 1-year high of $62.58. The company has a market cap of $1.97 billion, a price-to-earnings ratio of 3.06 and a beta of 0.87.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.